TY - JOUR
T1 - Testing of new agents in childhood cancer preclinical models
T2 - Meeting summary
AU - Houghton, Peter J.
AU - Adamson, Peter C.
AU - Blaney, Susan
AU - Fine, Howard A.
AU - Gorlick, Richard
AU - Haber, Michelle
AU - Helman, Lee
AU - Hirschfeld, Steve
AU - Hollingshead, Melinda G.
AU - Israel, Mark A.
AU - Lock, Richard B.
AU - Maris, John M.
AU - Merlino, Glenn
AU - Patterson, Wendy
AU - Reynolds, C. Patrick
AU - Shannon, Kevin
AU - Yu, Alice
AU - Yu, John
AU - Smith, Malcolm A.
PY - 2002/12/1
Y1 - 2002/12/1
N2 - A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop's presentations and discussions.
AB - A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop's presentations and discussions.
UR - http://www.scopus.com/inward/record.url?scp=0036896670&partnerID=8YFLogxK
M3 - 文献综述
C2 - 12473573
AN - SCOPUS:0036896670
SN - 1078-0432
VL - 8
SP - 3646
EP - 3657
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -